|Day Low/High||41.98 / 42.05|
|52 Wk Low/High||34.32 / 46.47|
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.
Traders should raise sell stops to just above $40 from below $35.50
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.
Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.
Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
Time to brace for a summer pullback?
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
The most recent short interest data has been released for the 07/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Investors may have been betting that the 'drug pricing war' was a non-event and that the upcoming earnings cycle would show continued growth and profitability in the healthcare sector.
Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 10 mg twice-daily (BID) for at least eight weeks, followed by XELJANZ 5 mg BID or 10 mg BID, for the treatment of adult patients with...
Major indexes gave ground in the final minutes of trade, but managed to stay in positive territory at the close.
Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.
Global stocks continued to edge lower Tuesday, as tech sector weakness bled into markets in Asia following last night's sell off on Wall Street, putting even more pressure on today's third quarter earnings report from Apple at the close of trading today.
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2018 and raised 2018 financial guidance for Adjusted diluted EPS (2).
U.S. stock futures are rising slightly on Tuesday ahead of earnings from Apple and as a two-day meeting of the Federal Reserve gets set to begin.
Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has approved TRAZIMERA™, 1 a biosimilar to Herceptin ®* (trastuzumab), for the treatment of human epidermal growth factor (HER2) overexpressing breast cancer and HER2 overexpressing...
Stocks ended lower on weakness in tech shares and after a strong report from Caterpillar proved insufficient to prop up the Dow.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
U.S. companies are on pace for one of the best earnings seasons in a decade, according to mid-term data from FactSet, with most firms appearing to have little or no concern for the impact of trade and tariffs on their bottoms lines over the coming months.
Shares fell on Friday morning despite positive results for the second quarter.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
The biotech giant will present detailed results of its mid-stage trials of BAN2401 at the Alzheimer's Association International Conference in Chicago.
Pfizer today announced it will increase its commitment to U.S.
ViiV Healthcare today presented 100-week results from its phase III programme evaluating the safety and efficacy of switching virologically-suppressed people living with HIV (PLHIV) from a three or four-drug antiretroviral regimen to a 2-drug regimen of...
ViiV Healthcare today presented at the 22 nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC)...
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #10 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Pfizer Inc also comes in above the median of analyst picks among the broader S&P 500 index components, claiming the #110 spot out of 500.
These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.